摘要
目的探讨调强放疗辅助XELOX方案治疗中晚期结直肠癌患者的疾病缓解率及其临床应用价值。方法选取2020年8月至2024年8月泉州市光前医院100例中晚期结直肠癌患者,依据随机数字表法分为两组。对照组患者行XELOX方案(奥沙利铂130 mg/m^(2)静脉滴注1 d+卡培他滨1000 mg/m^(2),2次/d,口服1~14 d)治疗,观察组行调强放疗辅助XELOX方案治疗。对比两组患者疾病缓解率及卡氏功能状态(KPS)、生存质量、肿瘤标志物。结果观察组疾病缓解率高于对照组(P<0.05);观察组治疗后KPS评分、生存质量评分均高于对照组(P<0.05);观察组治疗后血清肿瘤标志物水平均低于对照组(P<0.05)。结论调强放疗辅助XELOX方案治疗中晚期结直肠癌患者,可提高疾病缓解率,改善功能状态、生存质量,降低肿瘤标志物水平。
Objective To explore the disease remission rate and clinical value of intensity-modulated radiotherapy(IMRT)combined with the XELOX regimen(oxaliplatin and capecitabine)in treating patients with advanced colorectal cancer.Methods A total of 100 patients with advanced colorectal cancer in Quanzhou Guangqian Hospital from August 2020 to August 2024 patients were randomized into two groups by means of a random number table.Patients in the control group were treated with the XELOX regimen(intravenous infusion of oxaliplatin at 130 mg/m^(2) on 1 day+oral capecitabine at 1000 mg/m^(2) twice a day on 1-14 day),while those in the observation group were treated with intensity-modulated radiotherapy combined with the XELOX regimen.The disease remission rate,Karnofsky performance status(KPS),quality of life and tumor markers of the two groups of patients were compared.Results The observation group demonstrated greater disease remission rate than the control group(P<0.05).After treatment,the KPS score and quality of life were elevated in the observation group relative to the control group(P<0.05).The levels of serum tumor markers in the observation group after treatment were all lower than those in the control group(P<0.05).Conclusions IMRT combined with the XELOX regimen improves disease remission rate,functional status,and quality of life,while reducing serum tumor marker levels in patients with advanced colorectal cancer.
作者
龚伟
潘腾升
陈显诚
GONG Wei;PAN Tengsheng;CHEN Xiancheng(Department of Tumor Radiotherapy,Quanzhou Guangqian Hospital,Quanzhou,Fujian 362000,China)
出处
《中国医药指南》
2025年第21期90-92,共3页
Guide of China Medicine
关键词
结直肠癌
调强放疗
奥沙利铂
卡培他滨
肿瘤标志物
生存质量
Colorectal cancer
Intensity-modulated radiotherapy
Oxaliplatin
Capecitabine
Tumor markers
Quality of life
